|Table of Contents|

Prognostic value of Deauville 5-point scale and △SUV in follicular lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 03
Page:
477-480
Research Field:
Publishing date:

Info

Title:
Prognostic value of Deauville 5-point scale and △SUV in follicular lymphoma
Author(s):
Han Lei; Zhao Jinhua; Chen Xiang
Department of Nuclear Medicine，Shanghai General Hospital of Shanghai Jiaotong University，Shanghai 200080，China.
Keywords:
follicular lymphoma; tomography; emission-computed; X-ray computed; deoxyglucose; prognosis
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2019.03.029
Abstract:
Objective：We aimed to investigate the prognostic value of Deauville 5-point scale(5PS) and △SUV in follicular lymphoma（FL）.Methods：22 FL patients［10 males，12 females.Median age：56（22~88）years old］were retrospectively analyzed from May 2009 to March 2017，who had analyzable 18F-FDG PET/CT scans performed before and after 4 courses of chemotheraphy.Survival functions were estimated by Kaplan-Meier method between patients with Deauville 5-point scale<4 and patients with Deauville 5-point scale≥4.ROC curves were used for determining the best cutoff value of △SUVmax and △SUVmax % in predicting progress free survival（PFS）.Results：When applying the Deauville 5-point scale with a cutoff<4，the 24-month PFS was significantly longer than those applying a cutoff≥4（P=0.000）.12 patients（12/22，54.5%） resulted disease progressed within 2 years follow-up，while 10 patients（10/22，45.5%） didn' t result disease progressed.The mean values of △SUVmax were 2.8±3.4 and 6.9±2.6 in progressed group and non-progressed group（P=0.005）.The mean values of △SUVmax % disease progressed were （29.9±0.35）% and （80.6±0.09）% in progressed group and non-progressed group（P=0.001）.Conclusion：Deauville 5-point scale could assess prognostic value in FL patients after medium-term chemotherapy.

References:

［1］Chinese Society of Hematology，Chinese Medical Association.Chinese guidelines for the diagnosis and treatment of follicular lymphoma［J］.Chin J Hematol，2011，32(10)：717-720.［中华医学会血液学分会，中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南［J］.中华血液学杂志，2011，32(10)：717-720.］
［2］Le Dortz L，De Guibert S，Bayat S，et al.Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma［J］.Eur J Nucl Med Mol Imaging，2010，37：2307-2314.
［3］Bishu S，Quigley JM，Bishu SR，et al.Predictive value anddiagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma［J］.Leuk Lymphoma，2007，48：1548-1555.
［4］Trotman J，Fournier M，Lamy T，et al.Positron emission tomography-computed tomography(PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma：Analysis of PET-CT in a subset of PRIMA trial participants［J］.J Clin Oncol，2011，29：3194-3200.
［5］Dupuis J，Berriolo-Riedinger A，Julian A，et al.Impact of ［18F］fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy：A prospective study from the Groupe d' Etudes des lymphomes de l'Adulte and GOELAMS［J］.J Clin Oncol，2012，30：4317-4322.
［6］Wahl RL，Jacene H，Kaasamom Y，et al.From RECIST to PERCIST：Evolving considerations for PET response criteria in solid tumors［J］.J Nucl Med，2009，50(Suppl 1)：122S-150S.
［7］Bachy E，Brice P，Delarue R，et al.Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era：Effect of response quality on survival-a study from the groupe d'etude des lymphomes de l'adulte［J］.J Clin Oncol，2010，28：822-829.
［8］Buckstein R，Pennell N，Berinstein NL.What is remission in follicular lymphoma and what is its relevance［J］?Best Pract Res Clin Haematol，2005，18：27-56.
［9］Tsukamoto N，Kojima M，Hasegawa M，et al.The usefulness of
［18］F-fluorodeoxyglucose positron emission tomography ［(18)F-FDG-PET］ and a comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of lymphoma：Relation to histologic subtypes based on the World Health Organization classification［J］.Cancer，2007，110：652-659.
［10］Wirth A，Foo M，Seymour JF，et al.Impact of ［18F］fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma［J］.Int J Radiat Oncol Biol Phys，2008，71：213-219.
［11］Janikova A，Bolcak K，Pavlik T，et al.Value of ［18F］fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma：The end of a dilemma［J］?Clin Lymphoma Myeloma，2008，8：287-293.
［12］Scott AM，Gunawardana DH，Wong J，et al.Positron emission tomography changes management，improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma：Results of a multicentre prospective study［J］.Eur J Nucl Med Mol Imaging，2009，36：347-353.
［13］Luminari S，Biasoli I，Arcaini L，et al.The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma：A retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi［J］.Ann Oncol，2013，24：2108-2112.
［14］Pyo J，Won Kim K，Jacene HA，et al.End-therapy positron emission tomography for treatment response assessment in follicular lymphoma：A systematic review and Meta-analysis［J］.Clin Cancer Res，2013，19：6566-6577.
［15］Cheson BD，Pfistner B，Juweid ME，et al.Revised response criteriafor malignant lymphoma［J］.J Clin Oncol，2007，25：579-586..
［16］Juweid ME，Stroobants S，Hoekstra OS，et al.Useofpositronemissiontomography forresponse assessment of lymphoma：Consensus of the imaging subcommittee of international harmonization project in lymphoma［J］.J Clin Oncol，2007，25：571-578.
［17］Shankar LK，Hoffman JM，Bacharach S，et al.Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials［J］.J Nucl Med，2006，47：1059-1066.
［18］PET and Molecular Imaging Group of Chinese Society of Nuclear Medicine.Clinical practice guideline of 18F-FDG PET/CT in lymphoma(2016 edition)［J］.Chin J Nucl Med，2016，36：458-460.［中华医学会核医学分会PET与分子影像学组.淋巴瘤18F-FDG PET/CT显像临床应用指南(2016版)［J］.中华核医学与分子影像杂志，2016，36：458-460.］
［19］Kostakoglu L，Schoder H，Johnson JL，et al.Interim［(18)F］fluorodeoxyglucose positron emission tomography imaging in stage Ⅰ-Ⅱ non-bulky Hodgkin lymphoma：Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone［J］？Leuk Lymphoma，2012，53：2143-2150.
［20］Gao Yan，Zhao Jinhua，Song Jianhua，et al.Prognostic value of ΔSUV and Deauville 5-point scoring in patients with diffuse large B-cell lymphoma［J］.Chin J Nucl Med，2016，36(05)：420-425.［高艳，赵晋华，宋建华，等.△SUV法和Deauville五分法在弥漫性大B细胞淋巴瘤预后中的作用［J］.中华核医学与分子影像杂志，2016，36(05)：420-425.］
［21］Tychyj-Pinel C，Ricard F，Fulham M，et al.PET/CT assessment in follicular lymphoma using standardized criteria：Central review in the PRIMA study［J］.Eur J Nucl Med Mol Imaging，2014，41：408-415.
［22］Alcantara M，Dupuis J，Mareschal S，et al.PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma［J］.Eur J Nucl Med Mol Imaging，2015，42：215-221.
［23］Itti E，Meignan M，Berriolo-Riedinger A，et al.An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma：Comparison between Deauville criteria and △SUVmax［J］.Eur J Nucl Med Mol Imagin，2013，40(9)：1312-1320.
［24］Quak E，Hovhannisyan N，Lasnon C，et al.The importance of harmonizing interim positron emission tomography in non-Hodgkin lymphoma：Focus on the Deauville criteria［J］.Haematologica，2014，99(6)：e84-85.
［25］Meignan M，Gallamini A，Itti E，et al.Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton，France，26~27 September 2011 and Menton 2011 consensus［J］.Leuk Lymphoma，2012，53(10)：1876-1881.

Memo

Memo:
-
Last Update: 2018-12-29